Cargando…
Machine learning for pan-cancer classification based on RNA sequencing data
Despite recent improvements in cancer diagnostics, 2%-5% of all malignancies are still cancers of unknown primary (CUP), for which the tissue-of-origin (TOO) cannot be determined at the time of presentation. Since the primary site of cancer leads to the choice of optimal treatment, CUP patients pose...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667476/ https://www.ncbi.nlm.nih.gov/pubmed/38028533 http://dx.doi.org/10.3389/fmolb.2023.1285795 |
_version_ | 1785139258448674816 |
---|---|
author | Štancl, Paula Karlić, Rosa |
author_facet | Štancl, Paula Karlić, Rosa |
author_sort | Štancl, Paula |
collection | PubMed |
description | Despite recent improvements in cancer diagnostics, 2%-5% of all malignancies are still cancers of unknown primary (CUP), for which the tissue-of-origin (TOO) cannot be determined at the time of presentation. Since the primary site of cancer leads to the choice of optimal treatment, CUP patients pose a significant clinical challenge with limited treatment options. Data produced by large-scale cancer genomics initiatives, which aim to determine the genomic, epigenomic, and transcriptomic characteristics of a large number of individual patients of multiple cancer types, have led to the introduction of various methods that use machine learning to predict the TOO of cancer patients. In this review, we assess the reproducibility, interpretability, and robustness of results obtained by 20 recent studies that utilize different machine learning methods for TOO prediction based on RNA sequencing data, including their reported performance on independent data sets and identification of important features. Our review investigates the strengths and weaknesses of different methods, checks the correspondence of their results, and identifies potential issues with datasets used for model training and testing, assessing their potential usefulness in a clinical setting and suggesting future improvements. |
format | Online Article Text |
id | pubmed-10667476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106674762023-01-01 Machine learning for pan-cancer classification based on RNA sequencing data Štancl, Paula Karlić, Rosa Front Mol Biosci Molecular Biosciences Despite recent improvements in cancer diagnostics, 2%-5% of all malignancies are still cancers of unknown primary (CUP), for which the tissue-of-origin (TOO) cannot be determined at the time of presentation. Since the primary site of cancer leads to the choice of optimal treatment, CUP patients pose a significant clinical challenge with limited treatment options. Data produced by large-scale cancer genomics initiatives, which aim to determine the genomic, epigenomic, and transcriptomic characteristics of a large number of individual patients of multiple cancer types, have led to the introduction of various methods that use machine learning to predict the TOO of cancer patients. In this review, we assess the reproducibility, interpretability, and robustness of results obtained by 20 recent studies that utilize different machine learning methods for TOO prediction based on RNA sequencing data, including their reported performance on independent data sets and identification of important features. Our review investigates the strengths and weaknesses of different methods, checks the correspondence of their results, and identifies potential issues with datasets used for model training and testing, assessing their potential usefulness in a clinical setting and suggesting future improvements. Frontiers Media S.A. 2023-11-10 /pmc/articles/PMC10667476/ /pubmed/38028533 http://dx.doi.org/10.3389/fmolb.2023.1285795 Text en Copyright © 2023 Štancl and Karlić. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Štancl, Paula Karlić, Rosa Machine learning for pan-cancer classification based on RNA sequencing data |
title | Machine learning for pan-cancer classification based on RNA sequencing data |
title_full | Machine learning for pan-cancer classification based on RNA sequencing data |
title_fullStr | Machine learning for pan-cancer classification based on RNA sequencing data |
title_full_unstemmed | Machine learning for pan-cancer classification based on RNA sequencing data |
title_short | Machine learning for pan-cancer classification based on RNA sequencing data |
title_sort | machine learning for pan-cancer classification based on rna sequencing data |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667476/ https://www.ncbi.nlm.nih.gov/pubmed/38028533 http://dx.doi.org/10.3389/fmolb.2023.1285795 |
work_keys_str_mv | AT stanclpaula machinelearningforpancancerclassificationbasedonrnasequencingdata AT karlicrosa machinelearningforpancancerclassificationbasedonrnasequencingdata |